Discussing his outlook on pharma names, Pal said that he expects only a 10-12 percent growth in Lupin’s stock. Rating agencies Credit Suisse and Nomura had upgraded their ratings on the stock recently.
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
